PG
TMO icon

Prostatis Group’s Thermo Fisher Scientific TMO Stock Holding History

Prostatis Group’s Portfolio TMO Stock Details TMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.38M Buy
2,814
+136
+5% +$73.8K 0.35% 63
2025
Q4 		$1.55M Buy
2,678
+287
+12% +$162K 0.37% 57
2025
Q3 		$1.16M Hold
2,391
– – 0.29% 71
2025
Q2 		$969K Sell
2,391
-33
-1% -$13.8K 0.28% 74
2025
Q1 		$1.21M Sell
2,424
-71
-3% -$38.5K 0.38% 56
2024
Q4 		$1.3M Buy
2,495
+28
+1% +$15.4K 0.38% 61
2024
Q3 		$1.53M Sell
2,467
-82
-3% -$48.5K 0.5% 51
2024
Q2 		$1.41M Sell
2,549
-82
-3% -$47K 0.49% 54
2024
Q1 		$1.53M Sell
2,631
-91
-3% -$51.1K 0.58% 49
2023
Q4 		$1.44M Sell
2,722
-107
-4% -$51.8K 0.6% 43
2023
Q3 		$1.43M Sell
2,829
-1,449,265
-100% -$772M 0.7% 33
2023
Q2 		$1.47M Buy
1,452,094
+1,449,270
+51,320% +$782M 0.69% 36
2023
Q1 		$1.63M Sell
2,824
-2
-0.1% -$1.13K 0.86% 28
2022
Q4 		$1.56M Sell
2,826
-1,278
-31% -$677K 0.95% 30
2022
Q3 		$2.08M Buy
4,104
+1,193
+41% +$668K 2.4% 13
2022
Q2 		$1.58M Sell
2,911
-1,431
-33% -$788K 2.47% 5
2022
Q1 		$2.56M Buy
4,342
+149
+4% +$85.6K 2.06% 20
2021
Q4 		$2.8M Buy
4,193
+1,000
+31% +$624K 1.72% 21
2021
Q3 		$1.82M Hold
3,193
– – 1.09% 29
2021
Q2 		$1.61M Buy
3,193
+4
+0.1% +$1.89K 1.1% 28
2021
Q1 		$1.46M Buy
3,189
+17
+0.5% +$8.11K 1.14% 24
2020
Q4 		$1.48M Sell
3,172
-649
-17% -$304K 1.24% 20
2020
Q3 		$1.69M Sell
3,821
-6
-0.2% -$2.48K 1.6% 19
2020
Q2 		$1.39M Sell
3,827
-2,347
-38% -$787K 2.79% 9
2020
Q1 		$1.75M Sell
6,174
-548
-8% -$173K 2.49% 16
2019
Q4 		$2.18M Buy
+6,722
New +$2.04M 1.97% 16

Other funds holding TMO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Prostatis Group's TMO Position: Q1 2026 in Review

Prostatis Group increased its Thermo Fisher Scientific (TMO) stake by 5.1% in Q1 2026, buying an estimated $73.8K and bringing the position to 2,814 shares worth $1.38M. The position accounts for 0.35% of the portfolio, ranked #63.

Prostatis Group first reported a position in TMO in Q4 2019 and has held it in 26 quarters since. The position peaked at $2.8M in Q4 2021. 2,588 funds tracked by Wall St. Rank hold TMO as of Q1 2026.

  • Prostatis Group held 2,814 shares of Thermo Fisher Scientific worth $1.38M as of Q1 2026.
  • Prostatis Group bought 136 Thermo Fisher Scientific shares in Q1 2026, an estimated $73.8K.
  • Thermo Fisher Scientific made up 0.35% of Prostatis Group's portfolio in Q1 2026, its #63 holding.
  • Prostatis Group first reported a position in Thermo Fisher Scientific in Q4 2019 and has held it in 26 quarters since.
  • Prostatis Group's Thermo Fisher Scientific position peaked at $2.8M in Q4 2021.
  • 2,588 funds tracked by Wall St. Rank held Thermo Fisher Scientific as of Q1 2026.

Based on Prostatis Group's 13F filing for Q1 2026, filed 12 May 2026.